GU Cancers 2023 | Rationale + study design of UNITE: biomarkers of response to enfortumab vedotin in advanced UC

Tanya Jindal, BS, BA, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, shares the rationale and study design of the UNITE study investigating biomarkers of response to enfortumab vedotin (EV) in advanced urothelial carcinoma (UC). EV is approved for advanced treatment refractory UC, however, there’s limited data on biomarkers of response that can predict outcomes of EV treatment. The UNITE study looked at tumor mutation burden (TMB), somatic alterations, presence of one or more DNA damage response mutations. Patients were included who had at least one cycle of EV and had available next generation sequencing using institutional or commercial platforms. Observed response rate (ORR), progression-free survival (PFS), and overall-survival (OS) were evaluated. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.